Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
2.505
+0.095 (3.94%)
Jul 1, 2025, 1:51 PM - Market open
MRVI Stock Forecast
Stock Price Forecast
The 10 analysts that cover MRVI stock have a consensus rating of "Hold" and an average price target of $6.84, which forecasts a 173.05% increase in the stock price over the next year. The lowest target is $2 and the highest is $13.
Price Target: $6.84 (+173.05%)
Analyst Consensus: Hold
* Price targets were last updated on May 13, 2025.
Analyst Ratings
The average analyst rating for MRVI stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 1 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 4 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +299.20% | May 13, 2025 |
| Baird | Baird | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -20.16% | May 13, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +99.60% | Mar 25, 2025 |
| UBS | UBS | Hold Maintains $8 → $2.5 | Hold | Maintains | $8 → $2.5 | -0.20% | Mar 21, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +219.36% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
198.76M
from 259.19M
Decreased by -23.31%
Revenue Next Year
219.86M
from 198.76M
Increased by 10.62%
EPS This Year
-0.29
from -1.05
EPS Next Year
-0.23
from -0.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 215.3M | 245.7M | 304.9M | ||
| Avg | 198.8M | 219.9M | 248.9M | ||
| Low | 181.9M | 199.4M | 223.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -17.0% | 23.6% | 38.7% | ||
| Avg | -23.3% | 10.6% | 13.2% | ||
| Low | -29.8% | 0.3% | 1.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.19 | -0.07 | -0.06 | ||
| Avg | -0.29 | -0.23 | -0.17 | ||
| Low | -0.44 | -0.45 | -0.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.